药学学报, 2020, 55(4): 627-639
李卓, 贾瑞芳, 展鹏, 刘新泳. 寨卡病毒抑制剂研究新进展[J]. 药学学报, 2020, 55(4): 627-639.
LI Zhuo, JIA Rui-fang, ZHAN Peng, LIU Xin-yong. Progress on the discovery and development of anti-zika virus agents[J]. Acta Pharmaceutica Sinica, 2020, 55(4): 627-639.

李卓, 贾瑞芳, 展鹏, 刘新泳
山东大学药学院药物化学研究所, 化学生物学教育部重点实验室, 山东 济南 250012
关键词:    寨卡病毒      抗病毒药物      小分子      病毒靶点      宿主靶点      药物设计     
Progress on the discovery and development of anti-zika virus agents
LI Zhuo, JIA Rui-fang, ZHAN Peng, LIU Xin-yong
Department of Medicinal Chemistry, Key Laboratory of Chemical Biology(Ministry of Education), School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China
Zika virus (ZIKV) is a kind of mosquito-borne flavivirus. ZIKV infection initially shows mild symptoms on patients, but will lead to severe neurological complications (such as Guillain-Barré syndrome) in the end. Meanwhile, pregnant women are sensitive to ZIKV, since the viruses may cause microcephaly. In 2015, after the epidemic in Brazil, ZIKV draws the public attention around the world because of its increased virulence and rapid dissemination. However, there is no approved specific anti-ZIKV drugs at present. This review summarizes progress on anti-zika virus drug research and provides prospects in this field.
Key words:    Zika virus    antiviral agent    small molecule    virus target    host target    drug design   
收稿日期: 2019-09-11
DOI: 10.16438/j.0513-4870.2019-0748
基金项目: 国家自然科学基金重点国际合作研究项目(81420108027);国家自然科学基金面上项目(81573347,81273354);山东省重点研发计划(2017CXGC1401,2019JZZY021011).
通讯作者: 刘新泳,Tel:86-531-88380270,E-mail:xinyongl@sdu.edu.cn;展鹏,E-mail:zhanpeng1982@sdu.edu.cn
Email: xinyongl@sdu.edu.cn;zhanpeng1982@sdu.edu.cn
PDF(997KB) Free
李卓  在本刊中的所有文章
贾瑞芳  在本刊中的所有文章
展鹏  在本刊中的所有文章
刘新泳  在本刊中的所有文章

[1] Kuno G, Chang GJ, Tsuchiya KR, et al. Phylogeny of the genus flavivirus[J]. J Virol, 1998, 72:73-83.
[2] Dick GW. Zika virus. II. Pathogenicity and physical properties[J]. Trans R Soc Trop Med Hyg, 1952, 46:521-534.
[3] Simpson DI. Zika virus infection in man[J]. Trans R Soc Trop Med Hyg, 1964, 58:335-338.
[4] Zanluca C, Melo VC, Mosimann AL, et al. First report of autochthonous transmission of Zika virus in Brazil[J]. Mem Inst Oswaldo Cruz, 2015, 110:569-572.
[5] Hamelin ME, Baz M, Abed Y, et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets[J]. PLoS Pathog, 2010, 6:e1001015.
[6] Chambers TJ, Hahn CS, Galler R, et al. Flavivirus genome organization, expression, and replication[J]. Annu Rev Microbiol, 1990, 44:649-688.
[7] Hamel R, Dejarnac O, Wichit S, et al. Biology of Zika virus infection in human skin cells[J]. J Virol, 2015, 89:8880-8896.
[8] Van Hemert F, Berkhout B. Nucleotide composition of the Zika virus RNA genome and its codon usage[J]. Virol J, 2016, 13:95.
[9] Lindenbach BD, Rice CM. Molecular biology of flaviviruses[J]. Adv Virus Res, 2003, 59:23-61.
[10] Baz M, Boivin G. Antiviral agents in development for Zika virus infections[J]. Pharmaceuticals, 2019, 12:101.
[11] Chambers TJ, Weir RC, Grakoui A, et al. Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein[J]. Proc Natl Acad Sci U S A, 1990, 87:8898-8902.
[12] Wengler G, Czaya G, Farber PM, et al. In vitro synthesis of West Nile virus proteins indicates that the amino-terminal segment of the NS3 protein contains the active centre of the protease which cleaves the viral polyprotein after multiple basic amino acids[J]. J Gen Virol, 1991, 72:851-858.
[13] Li H, Clum S, You S, et al. The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids[J]. J Virol, 1999, 73:3108-3116.
[14] Takegami T, Sakamuro D, Furukawa T. Japanese encephalitis virus nonstructural protein NS3 has RNA binding and ATPase activities[J]. Virus Gen, 1995, 9:105-112.
[15] Bartelma G, Padmanabhan R. Expression, purification, and characterization of the RNA 5'-triphosphatase activity of dengue virus type 2 nonstructural protein 3[J]. Virology, 2002, 299:122-132.
[16] Guyatt KJ, Westaway EG, Khromykh AA. Expression and purification of enzymatically active recombinant RNA-dependent RNA polymerase (NS5) of the flavivirus Kunjin[J]. J Virol Methods, 2001, 92:37-44.
[17] Xie X, Gayen S, Kang C, et al. Membrane topology and function of dengue virus NS2A protein[J]. J Virol, 2013, 87:4609-4622.
[18] Erbel P, Schiering N, D'Arcy A, et al. Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus[J]. Nat Struct Mol Biol, 2006, 13:372-373.
[19] Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, et al. Inhibition of interferon signaling by dengue virus[J]. Proc Natl Acad Sci USA, 2003, 100:14333-14338.
[20] Roosendaal J, Westaway EG, Khromykh A, et al. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein[J]. J Virol, 2006, 80:4623-4632.
[21] Mackenzie JM, Jones MK, Young PR. Immunolocalization of the dengue virus nonstructural glycoprotein NS1 suggests a role in viral RNA replication[J]. Virology, 1996, 220:232-240.
[22] Batista MN, Braga ACS, Campos GRF, et al. Natural products isolated from oriental medicinal herbs inactivate Zika virus[J]. Viruses, 2019, 11:49.
[23] Haddad JG, Koishi AC, Gaudry A, et al. Doratoxylon apetalum, an indigenous medicinal plant from Mascarene Islands, is a potent inhibitor of Zika and Dengue virus infection in human cells[J]. Int J Mol Sci, 2019, 20:2382.
[24] Tychan Pte Ltd. Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in ZIKV Infected Patients. Clinical Trials. gov.NCT number:NCT03776695. 2018 Dec. NCT03776695. Available online:https://clinicaltrials.gov/ct2/show/NCT03776695(accessed on 30 May 2019).
[25] Niu X, Zhao L, Qu L, et al. Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model[J]. Emerg Microb Infect, 2019, 8:749-759.
[26] Duan W, Song H, Wang H, et al. The crystal structure of Zika virus NS5 reveals conserved drug targets[J]. EMBO J, 2017, 36:919-933.
[27] Eyer L, Nencka R, Huvarova I, et al. Nucleoside inhibitors of Zika virus[J]. J Infect Dis, 2016, 214:707-711.
[28] Arnold JJ, Sharma SD, Feng JY, et al. Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides[J]. PLoS Pathog, 2012, 8:e1003030.
[29] Chen YL, Yin Z, Lakshminarayana SB, et al. Inhibition of dengue virus by an ester prodrug of an adenosine analog[J]. Antimicrob Agents Chemother, 2010, 54:3255-3261.
[30] Furuta Y, Takahashi K, Shiraki K, et al. T-705(favipiravir) and related compounds:novel broad-spectrum inhibitors of RNA viral infections[J]. Antiviral Res, 2009, 82:95-102.
[31] Baz M, Goyette N, Griffin BD, et al. In vitro susceptibility of geographically and temporally distinct Zika viruses to favipiravir and ribavirin[J]. Antivir Ther, 2017, 22:613-618.
[32] Cai L, Sun Y, Song Y, et al. Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of Zika virus replication[J]. Arch Virol, 2017, 162:2847-2853.
[33] Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses[J]. Antiviral Res, 2018, 153:85-94.
[34] Reznik SE, Ashby CR Jr. Sofosbuvir:an antiviral drug with potential efficacy against Zika infection[J]. Int J Infect Dis, 2017, 55:29-30.
[35] Bullard-Feibelman KM, Govero J, Zhu Z, et al. The FDA-approved drug sofosbuvir inhibits Zika virus infection[J]. Antiviral Res, 2017, 137:134-140.
[36] Sacramento CQ, de Melo GR, de Freitas CS, et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication[J]. Sci Rep, 2017, 7:40920.
[37] Perales C, Domingo E. Antiviral strategies based on lethal mutagenesis and error threshold[J]. Curr Top Microbiol Immunol, 2016, 392:323-339.
[38] Lazear HM, Govero J, Smith AM, et al. A mouse model of Zika virus pathogenesis[J]. Cell Host Microbe, 2016, 19:720-730.
[39] Mangia A, Piazzolla V. Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies[J]. Dig Liver Dis, 2014, 46:179-185.
[40] Eyer L, Zouharova D, Sirmarova J, et al. Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-born eflaviviruses[J]. Antiviral Res, 2017, 142:63-67.
[41] Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430[J]. Nature, 2014, 508:402-405.
[42] Julander JG, Siddharthan V, Evans J, et al. Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model[J]. Antiviral Res, 2017, 137:14-22.
[43] Coutard B, Barral K, Lichière J, et al. Zika virus methyltransferase:structure and functions for drug design perspectives[J]. J Virol, 2017, 91:e02202-16.
[44] Zhang CY, Feng TT, Cheng JB, et al. Structure of the NS5 methyltransferase from Zika virus and implications in inhibitor design[J]. Biochem Biophys Res Commun, 2017, 492:624-630.
[45] Hamil RL, Hoehn MM. A9145, a new adenine-containing antifungal antibiotic. I. Discovery and isolation[J]. J Antibiot Tokyo, 1973, 26:463-465.
[46] Hercik K, Brynda J, Nencka R, et al. Structural basis of Zika virus methyltransferase inhibition by sinefungin[J]. Arch Virol, 2017, 162:2091-2096.
[47] Zhang J, Zheng YG. SAM/SAH analogs as versatile tools for SAM-dependent methyltransferases[J]. ACS Chem Biol, 2016, 11:583-597.
[48] Robert-Gero M, Lawrence F, Lederer E. Potential Clinical Use of Sinefungin:Reduction of Toxicity and Enhancement of Activity[M]//Hart DT. Leishmaniasis, Boston:Springer, 1989:79-883.
[49] Zhang Z, Li Y, Loh YR, et al. Crystal structure of unlinked NS2B-NS3 protease from Zika virus[J]. Science, 2016, 354:1597-1600.
[50] Nitsche C, Zhang L, Weigel LF, et al. Peptide-boronic acid inhibitors of flaviviral proteases:medicinal chemistry and structural biology[J]. J Med Chem, 2017, 60:511-516.
[51] Lei J, Hansen G, Nitsche C, et al. Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor[J]. Science, 2016, 353:503-505.
[52] Lee H, Ren J, Nocadello S, et al. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus[J]. Antiviral Res, 2017, 139:49-58.
[53] Li Y, Zhang Z, Phoo WW, et al. Structural dynamics of Zika virus NS2B-NS3 protease binding to dipeptide inhibitors[J]. Structure, 2017, 25:1242-1250.
[54] Li Y, Zhang Z, Phoo WW, et al. Structural insights into the inhibition of Zika virus NS2B-NS3 protease by a small-molecule inhibitor[J]. Structure, 2018, 26:555-564.
[55] Roy A, Lim L, Srivastava S, et al. Solution conformations of Zika NS2B-NS3pro and its inhibitionby natural products from edible plants[J]. PLoS One, 2017, 12:e0180632.
[56] Li Z, Brecher M, Deng YQ, et al. Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction[J]. Cell Res, 2017, 27:1046-1064.
[57] Jurgeit A, McDowell R, Moese S, et al. Niclosamide is a protoncarrier and targets acidic endosomes with broad antiviral effects[J]. PLoS Pathog, 2012, 8:e1002976.
[58] Xu M, Lee EM, Wen Z, et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen[J]. Nat Med, 2016, 22, 1101-1107.
[59] Yuan S, Chan JF, den-Haan H, et al. Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo[J]. Antiviral Res, 2017, 145:33-43.
[60] Phoo WW, Zhang Z, Wirawan M, et al. Structures of Zika virus NS2B-NS3 protease in complex with peptidomimetic inhibitors[J]. Antiviral Res, 2018, 160:17-24.
[61] Yao Y, Huo T, Lin YL, et al. Discovery, X-ray crystallography and antiviral activity of allosteric inhibitors of flavivirus NS2B-NS3 protease[J]. J Am Chem Soc, 2019, 141:6832-6836.
[62] Jain R, Coloma J, García-Sastre A, et al. Structure of the NS3 helicase from Zika virus[J]. Nat Struct Mol Biol, 2016, 23:752-754.
[63] Aguilar JS, Rice M, Wagner EK. The polysulfonated compound suramin blocks adsorption and lateraldifusion of herpes simplex virus type-1 in Vero cells[J]. Virology, 1999, 258:141-151.
[64] Baba M, Konno K, Shigeta S, et al. Selective inhibition of human cytomegalovirus replication by naphthalene disulfonic acid derivatives[J]. Antiviral Res, 1993, 20:223-233.
[65] Ellenbecker M, Lanchy JM, Lodmell JS. Inhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin[J]. Antimicrob Agents Chemother, 2014, 58:7405-7415.
[66] Wang Y, Qing J, Sun Y, et al. Suramin inhibits EV71 infection[J]. Antiviral Res, 2014, 103:1-6.
[67] Albulescu IC, Kovacikova K, Tas A, et al. Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles[J]. Antiviral Res, 2017, 143:230-236.
[68] Zhu S, Zhang C, Huang LS, et al. Discovery and computational analyses of novel small molecule Zika virus inhibitors[J]. Molecules, 2019, 24:1465.
[69] Deng YQ, Zhang NN, Li CF, et al. Adenosine analog NITD008 is a potent inhibitor of Zika virus[J]. Open Forum Infect Dis, 2016, 3:ofw175.
[70] Munjal A, Khandia R, Dhama K, et al. Advances in developing therapies to combat Zika virus:current knowledge and future perspectives[J]. Front Microbiol, 2017, 8:1469.
[71] Pascoalino BS, Courtemanche G, Cordeiro MT, et al. Zika antiviral chemotherapy:identification of drugs and promising starting points for drug discovery from an FDA-approved library[J]. F 1000Res, 2016, 5:2523.
[72] Barrows NJ, Campos RK, Powell ST, et al. A screen of FDA-approved drugs for inhibitors of Zika virus infection[J]. Cell Host Microbe, 2016, 20:259-270.
[73] Graci JD, Cameron CE. Mechanisms of action of ribavirin against distinct viruses[J]. Rev Med Virol, 2006, 16:37-48.
[74] Sidwell RW, Huffman JH, Khare GP, et al. Broad-spectrum antiviral activity of virazole:1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide[J]. Science, 1972, 177:705-706.
[75] Kamiyama N, Soma R, Hidano S, et al. Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremiain ZIKV-infected STAT1-deficient mice[J]. Antiviral Res, 2017, 146:1-11.
[76] Tong X, Smith J, Bukreyeva N, et al. Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens[J]. Antiviral Res, 2018, 149:34-40.
[77] Rausch K, Hackett BA, Weinbren NL, et al. Screening bioactives reveals nanchangmycin as a broad spectrum antiviral active against Zika virus[J]. Cell Rep, 2017, 18:804-815.
[78] Sarkey JP, Richards MP, Stubbs EB. Lovastatin attenuates nerve injury in an animal model of Guillain-Barre syndrome[J]. J Neurochem, 2007, 100:1265-1277.
[79] Kuivanen S, Bespalov MM, Nandania J, et al. Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism[J]. Antiviral Res, 2017, 139:117-128.
[80] Delvecchio R, Higa LM, Pezzuto P, et al. Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models[J]. Viruses, 2016, 8:322.
[81] Costa VV, Del Sarto JL, Rocha RF, et al. N-Methyl-d-aspartate (NMDA) receptor blockade prevents neuronal death induced by Zika virus infection[J]. MBio, 2017, 8:e00350-17.
[82] Retallack H, Di Lullo E, Arias C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin[J]. Proc Natl Acad Sci U S A, 2016, 113:14408-14413.
[83] Lin KJ, Mitchell AA, Yau WP, et al. Safety of macrolides during pregnancy[J]. Am J Obstet Gynecol, 2013, 208:221.e1-221.e8.
[84] Micewicz ED, Khachatoorian R, French SW, et al. Identification of novel small-molecule inhibitors of Zika virus infection[J]. Bioorg Med Chem Lett, 2018, 28:452-458.
[85] Kalanidhi P, Anjali J, Tugba M, et al. Anti-Zika activity of a library of synthetic carbohydrate receptors[J]. J Med Chem, 2019, 62:4110-4119.
1.修思雨, 张健, 鞠翰, 贾瑞芳, 黄兵, 展鹏, 刘新泳.抗流感病毒药物靶标及其小分子抑制剂的研究进展[J]. 药学学报, 2020,55(4): 611-626
2.宋淑, 高萍, 展鹏, 刘新泳.丙型肝炎病毒抑制剂研究进展[J]. 药学学报, 2020,55(4): 652-668
3.孙彦莹, 左晓芳, 展鹏, 刘新泳.抗腺病毒药物化学研究新进展[J]. 药学学报, 2020,55(4): 720-733
4.霍志鹏, 左晓芳, 康东伟, 展鹏, 刘新泳.抗艾滋病药物新靶标及其小分子抑制剂的研究进展[J]. 药学学报, 2018,53(3): 356-374